T.R. Jeffry Evans

13.1k citations

107 papers · 4.4k indexed · 1 hit paper · h-index 36

Impact in

Oncology top 1%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 63
- Pancreatic and Hepatic Oncology Research 20
- Cancer Treatment and Pharmacology 14
- Colorectal Cancer Treatments and Studies 13
- HER2/EGFR in Cancer Research 8
Cancer Research 24
- Cancer Genomics and Diagnostics 10

Co-authors: Owen J. Sansom Valerie G. Brunton Jennifer P. Morton Karin A. Oien Nigel B. Jamieson Margaret C. Frame R. Charles Coombes Saadia A. Karim
Journals: Journal of Clinical Oncology (33 papers)British Journal of Cancer (9 papers)Cancer Chemotherapy and Pharmacology (7 papers)Clinical Cancer Research (6 papers)European Journal of Cancer (6 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

T.R. Jeffry Evans

104 papers receiving 4.3k citations

Hit Papers

align trajectories log scale

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma 2014 · 438 citations

Peers

Countries citing papers authored by T.R. Jeffry Evans

Since Specialization

Citations

This map shows the geographic impact of T.R. Jeffry Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T.R. Jeffry Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T.R. Jeffry Evans more than expected).

Fields of papers citing papers by T.R. Jeffry Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T.R. Jeffry Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T.R. Jeffry Evans. The network helps show where T.R. Jeffry Evans may publish in the future.

Co-authors

The 25 scholars most cited alongside T.R. Jeffry Evans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with T.R. Jeffry Evans Line = papers co-authored together T.R. Jeffry Evans links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Improving surgical treatments for hepatocellular carcinoma Nature Reviews Gastroenterology & Hepatology ·Abdullah Malik, Daniel Geh, T.R. Jeffry Evans, Pierce K. H. Chow, Derek A. Mann, Steven White	2025	0
2	Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial. Journal of Clinical Oncology ·Jia Liu, Anna Minchom, Alastair Greystoke, T.R. Jeffry Evans, Debashis Sarker, Anthony M. Joshua, Cienne Morton, Burak Yasin Aktaş, Rasha Cosman, Dominika Chwialkowska, Jeremy Ra Paull, Nicola Jane Main, Bernadette Jean-Francois, Julia Le Meur, Stephanie R. Edmondson, Natalie Cook	2024	1
3	Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT Liver Cancer ·Richard S. Finn, Shukui Qin, Fabio Piscaglia, T.R. Jeffry Evans, Jennifer J. Knox, Carlos López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo	2024	1
4	Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study BMJ Open Gastroenterology ·Alistair S. McLaren, Johannes A. Spoor, Douglas Cartwright, Gregory Naylor, Stephen T. Barclay, Matthew Priest, Srikanth Puttagunta, Kirsty Armstrong, Stuart Ballantyne, Adrian J. Stanley, T.R. Jeffry Evans	2023	0
5	Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study Journal for ImmunoTherapy of Cancer ·Omid Hamid, Jessica C. Hassel, Alexander N. Shoushtari, Friedegund Meier, Todd M. Bauer, April K.S. Salama, John M. Kirkwood, Paolo A. Ascierto, Paul Lorigan, Cornelia Mauch, Marlana Orloff, T.R. Jeffry Evans, Chris Holland, Ramakrishna Edukulla, Shaad E. Abedin, Mark R. Middleton	2023	22
6	A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer British Journal of Cancer ·Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji	2023	22
7	Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers. Journal of Clinical Oncology ·Juanita Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clément, Heinz Läubli, Patrick Roth, T.R. Jeffry Evans, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Wing Yau, Benjamin Wunderlich, Kirk D. Beebe, Joel R. Eisner, Marc Engelhardt, Thomas Kaindl, Heidi A. Lane, Peter Hau, Thomas Hundsberger, Joachim P. Steinbach	2023	1
8	mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer Cancer Research ·David R. Driscoll, Saadia A. Karim, Makoto Sano, David M. Gay, Wright Jacob, Jun Yu, Yusuke Mizukami, Aarthi Gopinathan, Duncan I. Jodrell, T.R. Jeffry Evans, Nabeel Bardeesy, Michael N. Hall, Brian Quattrochi, David S. Klimstra, Simon T. Barry, Owen J. Sansom, Brian C. Lewis, Jennifer P. Morton	2016	58
9	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Igor Puzanov, Colin R. Lindsay, Laura W. Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Rich Gedrich, Andrew Stephens, Emily Chan, T.R. Jeffry Evans	2014	78
10	Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer Cancer Research ·Max Nobis, Ewan J. McGhee, Jennifer P. Morton, Juliane P. Schwarz, Saadia A. Karim, Jean A. Quinn, Mike Edward, Andrew D. Campbell, Lynn McGarry, T.R. Jeffry Evans, Valerie G. Brunton, Margaret C. Frame, Neil O. Carragher, Yingxiao Wang, Owen J. Sansom, Paul Timpson, Kurt I. Anderson	2013	99
11	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji	2013	97
12	A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours British Journal of Cancer ·David S. Boss, Hilary Glen, Jos H. Beijnen, M Keesen, R.S. Morrison, B. Tait, William Copalu, Antonina Joanna Mazur, J. Wanders, James P. O’Brien, Jan H.M. Schellens, T.R. Jeffry Evans	2012	150
13	A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours European Journal of Cancer ·Iain R. Macpherson, Srinivasu Poondru, George R. Simon, Richard Gedrich, Katie Brock, C. A. Hopkins, Kent D. Stewart, Andrew Stephens, T.R. Jeffry Evans	2012	10
14	MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Clinical Cancer Research ·Nigel B. Jamieson, Douglas C. Morran, Jennifer P. Morton, Asif Ali, Euan J. Dickson, C. Ross Carter, Owen J. Sansom, T.R. Jeffry Evans, Colin J. McKay, Karin A. Oien	2011	175
15	Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors Clinical Cancer Research ·George D. Demetri, Patricia Lo Russo, Iain R. Macpherson, Ding Wang, Jeffrey A. Morgan, Valerie G. Brunton, Prashni Paliwal, Shruti Agrawal, Maurizio Voi, T.R. Jeffry Evans	2009	126
16	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer Proceedings of the National Academy of Sciences ·Jennifer P. Morton, Paul Timpson, Saadia A. Karim, Rachel A. Ridgway, Dimitris Athineos, Brendan Doyle, Nigel B. Jamieson, Karin A. Oien, Andrew M. Lowy, Valerie G. Brunton, Margaret C. Frame, T.R. Jeffry Evans, Owen J. Sansom	2009	465
17	A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy Cancer Chemotherapy and Pharmacology ·Janet S. Graham, Stephen Falk, Leslie Samuel, Josep María Cendrós, T.R. Jeffry Evans	2008	8
18	Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors Annals of Oncology ·Eduardo Díaz‐Rubio, T.R. Jeffry Evans, Josep Tabernero, J Cassidy, Javier Sastre, Martin Eatock, D. Bisset, Pilar Regueiro, José Baselga	2002	88
19	Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy? European Journal of Cancer ·F. Lofts, T.R. Jeffry Evans, Janine Mansi, J.P. Glees, Marvin Knight	1997	17
20	Eosinophilic folliculitis occurring after bone marrow autograft in a patient with non-Hodgkin's lymphoma Cancer ·T.R. Jeffry Evans, Janine Mansi, R.H. Bull, Mary E. Fallowfield, David Bevan, Clive Harmer, Angus Dalgleish	1994	19

About T.R. Jeffry Evans

T.R. Jeffry Evans is a scholar working on Oncology, Cancer Research, Hepatology, Pulmonary and Respiratory Medicine and Hematology, having authored 107 papers that have together received 4.4k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (20 papers), Cancer Treatment and Pharmacology (14 papers), Colorectal Cancer Treatments and Studies (13 papers), Lung Cancer Treatments and Mutations (13 papers), Cancer Genomics and Diagnostics (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers), HER2/EGFR in Cancer Research (8 papers) and Estrogen and related hormone effects (8 papers). The work is most often cited by research in Oncology (1.9k citations), Hepatology (510 citations), Cancer Research (802 citations), Pathology and Forensic Medicine (667 citations) and Molecular Biology (1.8k citations). T.R. Jeffry Evans has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Owen J. Sansom, Valerie G. Brunton, Jennifer P. Morton, Karin A. Oien, Nigel B. Jamieson, Margaret C. Frame, R. Charles Coombes, Saadia A. Karim, Dimitris Athineos and Paul Timpson. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact